Hubbry Logo
Ephedra (plant)Ephedra (plant)Main
Open search
Ephedra (plant)
Community hub
Ephedra (plant)
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Ephedra (plant)
Ephedra (plant)
Ephedra (plant)
View on Wikipedia
from Wikipedia

Ephedra
Temporal range: Aptian–Recent
E. viridis Coville
Scientific classification Edit this classification
Kingdom: Plantae
Clade: Tracheophytes
Clade: Gymnospermae
Division: Gnetophyta
Class: Gnetopsida
Order: Ephedrales
Family: Ephedraceae
Genus: Ephedra
L.[1][2]
Type species
E. distachya[1]
Range of genus Ephedra
Synonyms[3]
1 synonym

Ephedra is a genus of gymnosperm shrubs. As of July 2025, 74 species, and two hybrids, are accepted.[3] The species of Ephedra are widespread in many arid regions of the world, ranging across southwestern North America, southern Europe, northern Africa, southwest and central Asia, northern China, and western South America.[3] It is the only extant genus in its family, Ephedraceae, and order, Ephedrales, and one of the three extant genera of the division Gnetophyta together with Gnetum and Welwitschia.

In temperate climates, most Ephedra species grow on shores or in sandy soils with direct sun exposure. Common names in English include joint-pine, jointfir, Mormon-tea, or Brigham tea. The Chinese name for Ephedra species is mahuang (simplified Chinese: 麻黄; traditional Chinese: 麻黃; pinyin: máhuáng; Wade–Giles: ma-huang; lit. 'hemp yellow'). Ephedra is the origin of the name of the stimulant ephedrine, which the plants contain in significant concentration.

E. fragilis Desf. male cones
E. distachya L. female cones with seeds
E. ciliata Fisch. & C.A.Mey. seed

Description

[edit]

The family Ephedraceae, of which Ephedra is the only extant genus, are gymnosperms, and generally shrubs, sometimes clambering vines, and rarely, small trees. Members of the genus frequently spread by the use of rhizomes.[4]

The stems are green and photosynthetic.[5] The leaves are opposite or whorled. The typical scalelike leaves are fused into a sheath at the base and is often shed soon after development. There are no resin canals.[4] Most species have rudimentary leaves without chlorophyll or photosynthesis, but a few, like E. altissima, develop normal, slender leaf-like leaves up to 5 cm (2.0 in) long and 0.5–1 mm (0.020–0.039 in) also as adults.[6]

The plants are mostly dioecious, with the pollen strobili in whorls of 1–10, each consisting of a series of decussate[7] bracts. The pollen is furrowed. The female strobili also occur in whorls, with bracts which fuse around a single ovule. Fleshy bracts are white (such as in E. frustillata) or red. There are generally 1–2 yellow to dark brown seeds per strobilus.[4]

Taxonomy

[edit]

The genus Ephedra was first described in 1753 by Carl Linnaeus.[1][2] The type species is E. distachya L..[1] The family, Ephedraceae, was first described in 1829 by Barthélemy Charles Joseph Dumortier.[8][9]

Evolutionary history

[edit]

The oldest known members of the genus are from the Early Cretaceous around 125 million years ago, with records being known from the Aptian-Albian of Argentina,[10] China,[11] Portugal and the United States.[12] The fossil record of Ephedra outside of pollen disappears after the Early Cretaceous.[13] Molecular clock estimates have suggested that last common ancestor of living Ephedra species lived much more recently, during the Early Oligocene around 30 million years ago.[14] However, pollen modified from the ancestral condition of the genus with branched pseudosulci (grooves), which evolved in parallel in the living North American and Asian lineages is known from the Late Cretaceous, suggesting that the last common ancestor is at least this old.[13]

Species

[edit]
Phylogeny of Ephedra[15][16]

As of July 2025, Plants of the World Online accepts the following 74 species, and two hybrids:[3]

Distribution

[edit]

The genus is found in dry and desert regions worldwide, except for Australia.[4]

Ecology

[edit]
E. foeminea Forssk. shrub in Kalbajar

Ephedraceae are adapted to extremely arid regions, growing often in high sunny habitats, and occur as high as 4,000 m (13,000 ft) above sea level in both the Andes and the Himalayas.[4] They make up a significant part of the North American Great Basin sage brush ecosystem.

Today, Ephedra plants are found no further south than 3°N in the Saharo-Arabian region. However, researchers have discovered evidence of this drought-resistant plant living over 1,000 km (620 mi) further south at Oldupai Gorge around one million years ago, based on fossil pollen, preserved tap roots, and supporting indicators of arid conditions.[17]

Human use

[edit]
Main article: Ephedra (medicine)
Plant as used in Chinese herbology (crude medicine)

Remains of a buried Neanderthal found at Shanidar cave in Iraqi Kurdistan, over 50,000 years old was found associated with Ephedra pollen among those of other plants. While some authors have suggested that these represent plant remains deliberately buried alongside the Neanderthal, other authors have suggested that natural agents like bees may have been responsible for the accumulation of pollen.[18]

In addition, archaeological remains of Ephedra dating back 15,000 years have been discovered at Taforalt Cave in Morocco. Fossil cones of Ephedra were found concentrated in the cemetery area, specifically within a human burial.[19]

The Ephedra alkaloids, ephedrine and pseudoephedrine – constituents of E. sinica and other members of the genus – have sympathomimetic and decongestant qualities,[20] and have been used as dietary supplements, mainly for weight loss.[21] The drug ephedrine is used to prevent low blood pressure during spinal anesthesia.[20]

In the United States, ephedra supplements were banned from the market in the early twenty-first century due to serious safety risks.[21] Plants of the genus Ephedra, including E. sinica and others, were used in traditional medicine for treating headache and respiratory infections, but there is no scientific evidence they are effective or safe for these purposes.[21]

Ephedra has also had a role as a precursor in the clandestine manufacture of methamphetamine.[22]

Adverse effects

[edit]

Alkaloids obtained from the species of Ephedra used in herbal medicines, such as pseudoephedrine and ephedrine, can cause cardiovascular events.[20] These events have been associated with arrhythmias, palpitations, tachycardia and myocardial infarction.[20] Caffeine consumption in combination with ephedrine has been reported to increase the risk of these cardiovascular events.[20][21]

Economic botany and alkaloid content

[edit]

The earliest uses of Ephedra species (mahuang) for specific illnesses date back to 5000 BC. Ephedrine and its isomers were isolated in 1881 from E. distachya and characterized by the Japanese organic chemist Nagai Nagayoshi. His work to access Ephedra's active ingredients to isolate a pure pharmaceutical substance led to the systematic production of semi-synthetic derivatives thereof and is still relevant today. Three species, E. sinica, E. vulgaris, and to a lesser extent E. equisetina, are commercially grown in Mainland China as a source for natural ephedrines and isomers for use in pharmaceuticals. E. sinica and E. distachya usually carry six optically active phenylethylamines, mostly ephedrine and pseudoephedrine with minor amounts of norephedrine, norpseudoephedrine as well as the three methylated analogs. Reliable information on the total alkaloid content of the crude drug is difficult to obtain. Based on HPLC analyses in industrial settings, the concentrations of total alkaloids in dried Herba Ephedra ranged between 1 and 4%, and in some cases up to 6%.[23]

For a review of the alkaloid distribution in different species of the genus Ephedra see Jian-fang Cui (1991).[24] Other American and European species of Ephedra, e.g. E. nevadensis (Nevada Mormon tea) have not been systematically assayed; based on unpublished field investigations, they contain very low levels (less than 0.1%) or none at all.[25]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Ephedra (plant)

View on Grokipedia
from Grokipedia

Ephedra is a of shrubs in the Ephedraceae, consisting of approximately 69 adapted to arid and semi-arid environments across , , and the . These plants feature profusely branched, jointed green stems with reduced, scale-like leaves, giving them a leafless, rush-like appearance reminiscent of horsetails. Ephedra have been utilized for thousands of years in , particularly in , for treating respiratory conditions like and colds due to alkaloids such as and , which act as sympathomimetics. The isolation of in 1885 enabled its synthesis and pharmaceutical applications, including as a and nasal . However, ephedra-containing dietary supplements for and athletic performance faced scrutiny for adverse cardiovascular events, leading to a U.S. FDA ban on ephedrine alkaloids in such products in 2004, a measure that substantially reduced associated poisonings and deaths. While traditional low-dose uses in herbal preparations persist in some cultures, the 's pharmacological potency underscores its dual role as both therapeutic agent and potential toxin when misused.

Description

Morphology

Ephedra species are shrubs or rarely vines adapted to arid and semi-arid environments, exhibiting xerophytic traits such as reduced surfaces and deep taproots for access. Habit varies from prostrate or low straggling forms to erect shrubs 0.5-2 m tall, with occasional climbing species reaching up to 4 m. Stems serve as the main photosynthetic organs, being green, prominently longitudinally ridged, and jointed with distinct nodes and elongated internodes; they are cylindrical to angular, 1-5 mm in at branch tips, and exhibit opposite or whorled dichotomous . Young stems are photosynthetic and , aging to gray or brown. Leaves are highly reduced to small, triangular, membranous scales, 1-8 mm long, arranged in opposite pairs or whorls of three at nodes; they are sessile, basally connate into a sheath encircling the stem, and typically soon after formation, leaving the persistent sheath. This reduction shifts photosynthetic function primarily to the stems. Ephedra plants are generally dioecious, with reproductive structures in cone-like strobili. Male pollen cones are axillary or terminal, ovoid to narrowly , 3-20 mm long, comprising 2-8 whorls of papery bracts; proximal bracts are empty, while distal ones are fused at the base and subtend microsporangiophores bearing 3-8 fused microsporangia each. Female seed cones are solitary or clustered, ovoid to , 5-40 mm long, with 3-8(10) whorls of bracts; the fertile bracts fuse to envelop one or rarely two inverted ovules, developing into seeds enclosed by a fleshy, often red or orange aril-like structure upon maturation.

Reproduction

Ephedra species exhibit predominantly dioecious reproduction, with male and female strobili borne on separate individuals, though rare monoecious species such as Ephedra campylopoda also occur. Male cones consist of whorls of microsporophylls, each bearing two microsporangia that produce bisaccate pollen grains adapted for wind dispersal. Female cones feature ovuliferous scales subtending one to several ovules, typically two per scale. Pollination is primarily anemophilous, facilitated by wind, across most species; however, basal taxa like Ephedra aphylla and Ephedra foeminea rely on insect vectors, including moths and flies. Female ovules exude a pollination droplet from the micropyle to capture airborne pollen, which is retracted to deposit sperm cells near the egg apparatus—a mechanism conserved among gymnosperms. Post-pollination, pollen tubes grow to deliver gametes, enabling fertilization and subsequent embryo development within the ovule. Mature seeds, numbering one or two per cone, feature either dry, winged integuments for wind dispersal or fleshy, brightly colored envelopes that attract avian dispersers in some species. Seed maturation typically spans from spring to late summer, varying by species and locale, with viable seeds not produced annually in all populations.

Taxonomy and Phylogeny

Evolutionary origins

The genus Ephedra originated in the Early Cretaceous period, with the earliest unequivocal macrofossils dating to the Aptian stage, approximately 125 to 113 million years ago. These include leafy shoots with articulated, striated axes and attached leaves, as well as seeds exhibiting diagnostic features such as apical papillae on the seed envelope and polyplicate pollen grains, found in deposits from Patagonia, Argentina, and Buarcos, Portugal. Additional Early Cretaceous fossils from Northeast China (Yixian Formation) and North America (Potomac Group) preserve female cones and whole plants showing morphological continuity with extant species, including naked male gametophytes and ephedroid branching patterns. Phylogenetically, Ephedra comprises the family Ephedraceae within Gnetophyta (Gnetales), a small clade of gymnosperms characterized by derived traits such as xylem vessels and compound leaves. Extant Gnetales form a monophyletic group, with Ephedra sister to the Gnetum-Welwitschia lineage, which diverged prior to 110 million years ago based on fossil-calibrated molecular phylogenies. Broader phylogenomic analyses place Gnetophyta as the sister group to conifers (specifically supporting the "gnetifer" hypothesis), embedding them within monophyletic gymnosperms and rejecting earlier anthophyte hypotheses that allied Gnetales with angiosperms. This positioning implies Ephedra's ancestors arose from early Mesozoic gnetalean stock, potentially traceable to Triassic dispersed polyplicate pollen attributable to the clade. Molecular divergence time estimates for the Ephedra crown group, derived from and nuclear loci like rbcL, suggest a younger origin around 8 to 32 million years ago ( to ), conflicting with the older fossil record. This discrepancy likely stems from low sequence divergence rates in Ephedra and calibration issues in relaxed clock models, as the fossil evidence provides a minimum age constraint indicating diversification rather than late relic survival. Such fossils underscore Ephedra's persistence through major climatic shifts, with modern clades reflecting geographic vicariance tied to and aridification.

Species diversity

The genus Ephedra comprises 74 accepted , reflecting ongoing taxonomic refinements based on morphological, anatomical, and molecular data. These vary in from low-growing, prostrate forms to erect shrubs reaching 2 meters in , with diversity driven by adaptations to xeric conditions and high rates of —observed in over 75% of the 51 evaluated cytogenetically. likely facilitates in fragmented arid habitats, contributing to infraspecific variation and hybrid zones. Infrageneric classification divides Ephedra into sections primarily based on reproductive structures, such as ovulate cone bract fusion and morphology, as outlined in early systems like Meyer's () division into Plagiostoma (now Ephedra) and other groups, later expanded by Stapf () to include Alatae. Section Alatae features winged branchlets and is represented in and the , while section Ephedra encompasses species with fused and dominates in . Phylogenetic analyses support two primary clades: a derived North American group with about 11 species characterized by large seeds and ant-dispersal adaptations, and a paraphyletic clade containing the remainder, basal members of which (e.g., E. aphylla, E. foeminea) exhibit insect pollination unlike the wind-pollinated majority. Species diversity peaks in and the Mediterranean Basin, with and hosting over 30 species collectively, often endemic to and floras; supports fewer, with endemics concentrated in the and . South American occurrences are limited to a handful of species in Andean and Patagonian arid zones. Hybridization occurs but is rare, complicating delineation in overlapping ranges, as seen in taxa like E. × arenicola. Overall, arid adaptation and relictual distributions from ancestors underpin the genus's moderate diversity relative to more speciose genera.

Distribution and Habitat

Global patterns

The genus Ephedra comprises approximately 69 species distributed primarily in arid and semi-arid regions across the , with extensions into southern . These plants favor dry habitats such as deserts, steppes, and rocky slopes, ranging from to altitudes exceeding 5,000 meters. The highest species diversity occurs in , particularly in central and southwestern regions, where environmental conditions like low and high support proliferation. In , around 21 species are concentrated, with 18 in and four around the Mediterranean Basin, including parts of and . distributions include two species, one extending into southwestern , while European occurrences are limited to Mediterranean coastal and inland dry areas. In , species are restricted to the and , forming a distinct adapted to ecosystems like the and . South American representation is minimal, with a single species (Ephedra breana) found in the Andean regions of and , extending as far south as . Global patterns reflect ancient dispersals, with phylogenetic evidence indicating origins in the Mediterranean region followed by eastward migration to and separate radiations. Disjunct distributions highlight adaptations to similar xeric conditions across continents, though no native species occur in or tropical rainforests, underscoring a preference for temperate and subtropical over humid or polar extremes beyond limited northern extensions. Climate modeling predicts potential shifts in suitable ranges under future warming, with expansions in high-altitude Asian zones but contractions in lower-latitude arid areas due to increased aridity.

Environmental adaptations

Ephedra species demonstrate pronounced adaptations to arid and semi-arid climates, inhabiting regions from below sea level to altitudes exceeding 5,000 meters, including deserts, steppes, and high plateaus across Asia, Europe, North Africa, and the Americas. These gymnosperms persist as perennial shrubs or occasional vines in environments characterized by low precipitation, high temperatures, and seasonal droughts, functioning as pioneer plants on sand dunes and degraded soils where they stabilize substrates and mitigate erosion. Morphologically, Ephedra exhibits xeromorphic traits such as reduced, scale-like leaves that early to curtail transpirational losses, with primary occurring in the persistent green stems. Deep systems facilitate access to subsurface in dry soils, enhancing survival during prolonged dry periods. Physiologically, species like E. alata employ an anisohydric strategy, maintaining under diminishing water potentials down to -3.5 MPa, which prioritizes carbon assimilation over strict but risks hydraulic failure. This is complemented by rapid post-drought recovery, with photosynthetic rates and relative restoring to pre-stress levels within 48 hours of rewatering, aided by osmotic adjustment through accumulation increasing up to 480%. Edaphically, Ephedra tolerates a broad range of soils, including , weakly saline, and sodic substrates, while thriving in well-drained, coarse-textured media and avoiding waterlogged conditions. Secondary metabolites, such as alkaloids, may contribute to stress resilience by deterring herbivores and pathogens in nutrient-poor, harsh habitats. Many species resprout vigorously from root crowns following fire or disturbance, underscoring their role in post-disturbance recolonization of arid landscapes.

Ecology

Pollination and seed dispersal

Ephedra species are dioecious gymnosperms, bearing separate and cones, with predominantly anemophilous via dispersal of lightweight from male strobili to ovules on female cones. Female ovules secrete a sticky drop that captures airborne grains, facilitating selective deposition based on pollen size and density, as observed in species like Ephedra trifurca where droplets preferentially trap conspecific pollen over competitors. This mechanism aligns with the aerodynamic adaptations of Ephedra , including promoting clump formation and efficient transport. However, basal lineages such as E. aphylla and E. foeminea exhibit , with insect vectors pollinating via nectar-like rewards on cones, representing an ancestral state from which evolved in derived clades. Seed dispersal in Ephedra varies by species and geography, with the dispersal unit typically comprising the seed cone featuring modified bracts that influence mode. North American species display three syndromes: anemochory in taxa like E. torreyana and E. trifurca via dry, winged bracts enabling wind transport; myrmecochory or scatter-hoarding by in large-seeded forms such as E. viridis, where animals cache propagules in for later retrieval or abandonment; and limited ornithochory or saurochory involving fleshy, colorful bracts attractive to birds or , though mediation predominates. In Asian species, frugivory prevails, with seed envelopes bearing transverse lamellae or papillae that enhance adhesion to avian or mammalian dispersers, contrasting anemochoric American counterparts with similar microstructures. These adaptations correlate with environmental pressures, such as favoring caching for burial and protection, and fleshy structures promoting endozoochory in mesic habitats.

Biotic interactions

Ephedra species experience herbivory primarily from mammalian browsers, including pronghorn antelope (Antilocapra americana), (Odocoileus hemionus), (Cervus canadensis), and livestock such as sheep (Ovis aries) and (Capra aegagrus hircus), which consume the photosynthetic stems. In the Nepal Himalayas, sheep and goats exhibit preferential browsing on wild Ephedra stocks, potentially exerting population-level pressure on the plants. While male sheep and cattle tolerate consumption without apparent ill effects, pregnant females face risks from ephedrine alkaloids, which can induce toxicity. Insect herbivory influences Ephedra's defensive chemistry, with pressures from feeding damage prompting elevated alkaloid production as a deterrent. Ephedrine, a key alkaloid, exhibits toxicity toward insect herbivores such as weevils, reducing damage to non-shedding photosynthetic stems during dormancy periods. Ephedra maintains mutualistic associations with endophytic fungi, which colonize stems, leaves, and roots, coevolving to enhance host physiology and secondary metabolism. These symbionts promote plant growth promotion and correlate with increased accumulation of bioactive alkaloids like ephedrine in stems of species such as Ephedra sinica, particularly in older growth stages. Endophyte diversity varies by tissue and environmental conditions, with interactions mediated by plant hormones such as auxin and ethylene. Biotic seed dispersal in North American Ephedra involves scatter-hoarding , which collect and cache fleshy of species like , facilitating when caches are forgotten. Birds and contribute to dispersal in certain taxa, attracted to conspicuous morphology, contrasting with dispersal in other species. These interactions represent adaptive syndromes that have evolved multiple times in arid habitats.

Phytochemistry

Alkaloid profiles

The stems of Ephedra species primarily contain phenylpropanoid , including , , norephedrine, norpseudoephedrine, N-methylephedrine, and N-methylpseudoephedrine, which constitute the majority of the plant's bioactive nitrogenous compounds. These amphetamine-like alkaloids account for up to 90-99% of total alkaloid content in pharmacologically significant , with concentrations varying from 0.1% to over 2% dry weight depending on , environment, and harvest conditions. Roots, by contrast, are richer in macrocyclic alkaloids such as ephedradine A, B, and D, alongside derivatives like feruloylhistamine. Ephedrine predominates in species like Ephedra sinica and Ephedra major, often comprising 1-2% of stem dry weight, while pseudoephedrine is more abundant in Ephedra monosperma. Ephedra intermedia exhibits lower total alkaloid levels (approximately 0.94% dry weight) compared to E. sinica, with a reduced ephedrine-to-pseudoephedrine ratio. Stereochemical profiles also differ; E. sinica accumulates primarily (1R,2S)-ephedrine, whereas other species may favor alternative isomers. Total alkaloid content (TAC) in stems ranges widely, as shown below for select species (mg/g dry weight):
SpeciesTAC (spectrophotometry)Dominant Alkaloid(s)
E. distachya subsp. helvetica15.8 ± 0.0
E. major14.8 ± 1.9
E. monospermaNot specified
E. fragilis0.2 ± 0.0
Such intraspecific and interspecific variability underscores the influence of taxonomic and ecological factors on biosynthesis, with higher elevations often correlating with elevated levels in E. sinica and relatives. Over 29 alkaloids have been identified across the genus, including minor , , and types, but analogs drive the pharmacological profile.

Biosynthetic pathways

The biosynthesis of ephedrine and pseudoephedrine in Ephedra species derives from L-phenylalanine as the primary precursor for the benzylic C6-C1 unit, confirmed through pulse-labeling experiments showing and side-chain shortening. (PAL) initiates the pathway by converting L-phenylalanine to , which undergoes β-oxidative or non-β-oxidative degradation to or derivatives, providing the phenylpropanoid scaffold. The propanoid chain assembles via of the intermediate with pyruvate, yielding 1-phenylpropane-1,2-dione as a key diketone precursor, as evidenced by tracer incorporation studies. This step parallels acyloin mechanisms, followed by stereospecific reduction of the keto groups and to introduce the functionality, forming norephedrine or norpseudoephedrine. Alternative routes involving phosphate-dependent carboligation of benzoyl-CoA with L-alanine to , bypassing the dione, have been proposed but require further validation in planta. The terminal N-methylation occurs via phenylalkylamine N-methyltransferase (PaNMT), isolated from Ephedra sinica, which uses S-adenosylmethionine (SAM) as the methyl donor to convert norephedrine (Km = 1.2 mM) to ephedrine and norpseudoephedrine (Km = 1.7 mM) to pseudoephedrine, exhibiting broad substrate tolerance but lacking strict stereospecificity. This enzyme operates optimally at pH 9.0 and 50°C, with Vmax values ranging from 0.19–1.51 pmol s⁻¹ mg⁻¹. While early steps rely on inferred mechanisms from feeding experiments, PaNMT represents a cloned component enabling heterologous production. The pathway's localization in stems correlates with higher alkaloid accumulation compared to roots.

Traditional and Modern Uses

Ethnobotanical history

Ephedra species have been employed in traditional medicine across arid regions for millennia, primarily for their stimulant and bronchodilatory effects attributed to alkaloids like ephedrine. In Traditional Chinese Medicine, Ephedra sinica (known as Ma Huang) has been documented for over 5,000 years to treat respiratory ailments such as cough, asthma, colds, fever, and flu, often to dispel "wind-cold" patterns by inducing perspiration and opening airways. Its earliest textual references appear in ancient pharmacopeias like the Shennong Bencao Jing (circa 1st-2nd century AD), though oral traditions suggest even earlier use dating to prehistoric times. In , Ephedra gerardiana holds a place in Ayurvedic medicine, where it has been utilized since ancient times for conditions including , , fever, , and heart disorders, often prepared as decoctions to alleviate swelling and respiratory distress. Similar applications extended to the , with species like Ephedra alata and Ephedra campylopoda employed by traditional healers in and for , , and bacterial infections, leveraging the plant's properties in topical and oral forms. In the , indigenous groups such as the , Paiute, and Pima utilized North American species like Ephedra antisyphilitica, Ephedra nevadensis, and Ephedra trifurca (collectively known as Mormon tea) to address stomach aches, kidney problems, , , and respiratory issues like colds and coughs, typically via teas brewed from stems. These practices were later adopted by in the , who prepared the caffeine-free beverage as a mild tonic and substitute for imported teas, continuing Native American methods for medicinal and social purposes. In , species including Ephedra pedunculata served analogous roles in treating , , and venereal diseases.

Pharmacological mechanisms

The principal pharmacological effects of Ephedra species derive from their alkaloids, primarily and , which constitute up to 2-3% of dry weight in species like . These compounds function as sympathomimetic agents, mimicking the actions of endogenous catecholamines such as norepinephrine and epinephrine. , the dominant alkaloid, operates via dual mechanisms: indirect sympathomimetic activity through the release of norepinephrine from presynaptic sympathetic nerve terminals and inhibition of its , alongside weaker direct at α- and β-adrenergic receptors. This leads to enhanced activation, with peak plasma concentrations achieved approximately 1-2 hours post-oral administration and a of around 88%. In the cardiovascular system, ephedrine stimulates β1-adrenergic receptors in the myocardium, increasing and contractility via elevated cyclic AMP levels, while α1-receptor activation promotes peripheral , elevating systolic . Respiratory effects stem from β2-adrenergic agonism, inducing bronchodilation by relaxing bronchial , which underlies historical uses for relief. Central nervous system stimulation occurs through norepinephrine release in the , contributing to and mild , though exhibits comparatively reduced α-receptor affinity, resulting in less pronounced vasoconstrictive effects. Secondary compounds in Ephedra, such as and , exhibit ancillary mechanisms including modulation via inhibition of pro-inflammatory cytokines and activity through scavenging , though these are less dominant than alkaloid-driven sympathomimesis. Biosynthetic pathways in the plant yield these alkaloids from via and , but human pharmacological outcomes hinge on receptor-mediated signaling rather than plant-endogenous processes. Empirical data from isolated alkaloid studies confirm non-selective adrenergic as the core mechanism, with dose-dependent variability in effects observed in normotensive adults.

Regulation and Controversies

Historical regulatory actions

In the United States, ephedra-containing dietary supplements faced increasing regulatory pressure starting in the mid-1990s amid rising adverse event reports linked to ephedrine alkaloids. Between 1993 and , the (FDA) documented over 800 such reports, leading to a proposed rule in that would limit dosages to 8 mg of ephedrine alkaloids per serving, mandate warning labels, and enforce good manufacturing practices. These measures encountered resistance from industry groups arguing for self-regulation and low-dose safety, delaying implementation. By 2000, the FDA escalated by proposing a full ban on ephedra in dietary supplements, concluding that the alkaloids posed significant risks—including cardiovascular events like heart attacks and strokes—outweighing any unsubstantiated benefits for or performance enhancement, based on meta-analyses of and post-market . Legal challenges and further protracted the process, even as high-profile fatalities, such as the 2003 death of a prospect attributed to ephedra, highlighted enforcement gaps. On February 11, 2004, the FDA finalized the rule deeming such supplements adulterated under the Federal Food, Drug, and Cosmetic Act, prohibiting their sale effective April 12, 2004. Preceding the federal action, individual states acted independently; , for example, banned ephedrine alkaloid supplements effective October 19, 2003, following legislative approval in August. Internationally, responses diverged: suspended sales of ephedra supplements in 2002 citing similar safety concerns, while the restricted ephedrine alkaloids in foodstuffs around 2004 under regulations. Ephedrine as a synthetic pharmaceutical remains regulated but available by prescription in many jurisdictions, distinct from unregulated plant extracts. In sports, the banned ephedra since the 1990s due to its sympathomimetic effects enhancing performance.

Risk-benefit analyses

A of 19 randomized controlled trials published in 2003 evaluated the efficacy and safety of ephedra and for and athletic performance, finding modest short-term weight reduction of approximately 0.9 kg per month greater than , with no significant effects on athletic outcomes such as or strength. The analysis reported increased risks of mild autonomic effects like gastrointestinal distress, dry mouth, and (odds ratio 2.17), alongside rare psychiatric symptoms, but noted insufficient data on serious adverse events within trials, though post-marketing reports included cardiovascular incidents. A 2003 RAND Corporation evidence review corroborated these findings, concluding that ephedra-containing products yield short-term weight loss benefits comparable to pharmaceutical (about 2 kg over 4-6 months), potentially through sympathomimetic mechanisms enhancing and suppression, but emphasized elevated risks of side effects and associations with severe outcomes like , , and death in observational data. The review highlighted that benefits diminish without long-term adherence, while risks amplify with combinations like , which potentiate cardiovascular strain via synergistic adrenergic stimulation. More recent systematic reviews provide nuanced updates; a 2021 meta-analysis of ephedrine-containing products demonstrated greater (mean difference -1.97 kg vs. ) and favorable shifts, including reduced triglycerides and total , but observed significant increases (mean difference 2.87 bpm) without consistent elevations. A 2024 of ephedra-containing oral medications, drawing from 20 randomized trials primarily in contexts, affirmed dose-dependent weight reduction efficacy, attributing it to sympathetic activation and modulation, yet documented adverse events like and in 10-20% of participants, underscoring the need for monitored use. In respiratory applications, such as for or congestion, ephedra's bronchodilatory effects via beta-2 offer benefits in traditional low-dose formulations, with historical evidence from controlled studies showing symptom relief comparable to mild sympathomimetics, though modern analyses reveal risk disparities: pharmaceutical at 15-25 mg doses exhibits lower event rates than unregulated herbal extracts exceeding 20 mg ephedrine equivalents. Overall assessments, including those informing the 2004 U.S. FDA ban on ephedra supplements, weigh modest, transient benefits against disproportionate real-world risks—particularly cerebrovascular and cardiac events in susceptible individuals (e.g., those with or arrhythmias)—concluding that unsupervised use fails cost-benefit thresholds absent rigorous dosing and screening.

Safety Profile

Documented adverse events

Dietary supplements containing ephedra alkaloids have been linked to serious adverse events, including cardiovascular complications such as , , , and , as documented in reports to the U.S. (FDA). A review of 140 FDA reports from June 1997 to March 1999 identified 62 cardiovascular events (47% of those assessed as related or possibly related), with common symptoms including (17 cases) and palpitations or (13 cases); these events often occurred at recommended doses (12–36 mg/day) in otherwise healthy individuals. Similarly, approximately 500 adverse event reports to the Department of Health from December 1993 to September 1995 included severe cardiovascular outcomes ranging from to death. Central nervous system events, such as seizures and strokes, were also prevalent, comprising 18% of related cases in the FDA analysis, with 10 strokes and 7 seizures reported; 31% of all 140 cases were deemed definitely or probably related to ephedra use, while another 31% were possibly related. Psychiatric adverse events, including (reported in 56% of serious cases), severe depression, , hallucinations, disturbances, and , emerged in an analysis of 1,820 FDA reports, with 57 serious psychiatric events noted, 26 involving hospitalizations (at least 6 involuntary); however, two-thirds of these cases involved preexisting psychiatric conditions or concurrent use of other substances. Fatalities represent the most severe documented outcomes, with 10 deaths (including one neonatal and one fetal) in the 140-report FDA sample, often tied to cardiovascular or cerebrovascular causes, and causality rated as definite, probable, or possible in a subset. In the Texas reports, 8 deaths were recorded, 7 attributed to myocardial infarction or cerebrovascular accident. Overall, the FDA received 2,277 adverse event reports associated with ephedra-containing supplements from February 1993 onward, far exceeding reports for other herbal products, contributing to regulatory scrutiny. Permanent disability occurred in 13 cases (26% of definite/probable/possible events) in the reviewed FDA data, underscoring risks even with short-term, low-dose use.

Comparative risk assessments

Ephedra alkaloids, particularly , have been associated with a of adverse reactions substantially higher than that of other herbal products in analyses of reported events. A study examining U.S. data from 1997–1999 found the for any adverse reaction with ephedra use ranged from 100 (95% CI, 83–140) compared to to over 800 (95% CI, 500–1300) compared to , with emergency visits showing similarly elevated odds ratios up to 31 (95% CI, 26–38). These disparities stem from ephedra's sympathomimetic effects, which more frequently trigger cardiovascular and symptoms than the milder profiles of non-stimulant herbs. In comparison to other stimulants, ephedra and exhibit stronger pressor and effects than alone or . Experimental data indicate elevates and more than equivalent doses of , with combinations of and amplifying these responses via synergistic adrenergic stimulation, increasing risks of and arrhythmias beyond either agent singly. , a stereoisomer with weaker central and hypertensive activity, shows reduced and stimulating effects relative to , contributing to its continued availability in decongestants despite shared mechanisms. Relative to pharmaceutical NSAIDs or aspirin, ephedra's risks differ in profile and context: NSAIDs carry higher chronic gastrointestinal and renal mortality (e.g., one nationwide study estimated substantial attributable deaths, though confounded by low-dose aspirin use), while ephedra's concerns center on acute cardiovascular events like or in otherwise healthy users, with case series linking it to such outcomes at rates prompting regulatory bans despite lower overall dose volumes. A retrospective analysis of prescribed /caffeine combinations in (2000–2005) reported no significant increase in cardiovascular endpoints (hazard ratio near 1.0), contrasting with supplement-associated reports where adulterants or high doses elevated perils, though absolute mortality remained rare (e.g., extrapolated at 1 per billions of doses in proponent critiques). Recent meta-analyses of ephedra-containing medications for conditions like found no excess adverse events versus controls (RR 0.99, 95% CI 0.80–1.22), suggesting context-dependent safety in controlled pharmaceutical forms versus unregulated supplements.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC7397145/
  2. https://www.sciencedirect.com/topics/medicine-and-dentistry/ephedra-plant
  3. https://www.nccih.nih.gov/health/ephedra
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC7210547/
  5. https://ods.od.nih.gov/factsheets/EphedraandEphedrine-HealthProfessional/
  6. https://www.nejm.org/doi/full/10.1056/NEJMc1502505
  7. https://ucjeps.berkeley.edu/eflora/eflora_display.php?tid=30
  8. https://conifers.org/ep/Ephedraceae.php
  9. https://milnepublishing.geneseo.edu/botany/chapter/ephedra-jointfir/
  10. https://www.biologydiscussion.com/gymnosperm/ephedra/ephedra-distribution-features-and-reproduction/53366
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC11591873/
  12. https://plants.usda.gov/DocumentLibrary/plantguide/pdf/cs_epvi.pdf
  13. https://bio.libretexts.org/Bookshelves/Botany/Inanimate_Life_%28Briggs%29/02%253A_Organisms/2.18%253A_Ephedra_-_Jointfir
  14. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/ephedraceae
  15. https://greatbasinseeds.com/product/nevada-ephedra/
  16. https://pubmed.ncbi.nlm.nih.gov/28528483/
  17. https://www.pnas.org/doi/10.1073/pnas.0407588101
  18. https://www.journals.uchicago.edu/doi/10.1086/605116
  19. https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:328160-2
  20. https://www.sciencedirect.com/science/article/abs/pii/S1055790304004105
  21. https://scholarship.claremont.edu/cgi/viewcontent.cgi?article=1395&context=aliso
  22. https://www.researchgate.net/publication/383686702_Taxonomic_Revision_of_Genus_Ephedra_Tourn_ex_L_in_Egypt_with_Intra-Gender_Diversity_in_Morphometric_Traits_and_Fatty_Acid_Composition
  23. https://www.fs.usda.gov/nsl/Wpsm/Ephedra.pdf
  24. https://www.researchgate.net/publication/225340124_Evolution_of_seed_dispersal_in_North_American_Ephedra
  25. https://plants.usda.gov/classification/15691
  26. http://www.worldbotanical.com/ephedra.htm
  27. https://floranorthamerica.org/Ephedra
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC10975542/
  29. https://escholarship.org/content/qt26k2v84q/qt26k2v84q.pdf
  30. https://www.fs.usda.gov/database/feis/plants/shrub/ephvir/all.html
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC4424609/
  32. https://www.journals.uchicago.edu/doi/abs/10.1086/337757
  33. https://www.academia.edu/27815135/Aerodynamics_and_pollen_ultrastructure_in_Ephedra
  34. https://www.diva-portal.org/smash/get/diva2:1082324/FULLTEXT01.pdf
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC8851845/
  36. https://www.journals.uchicago.edu/doi/abs/10.1086/596334
  37. https://www.uaf.edu/ail/files/Ickert-Bond_Rydin_EphedraSeeds_IJPS2011.pdf
  38. https://www.frontierbotany.info/projects/nw-ephedra-trait-evolution-and-plant-animal-interactions/
  39. https://www.colorado.edu/asmagazine/2023/03/03/mormon-tea-has-no-flowers-or-leaves-lots-history
  40. https://www.jstage.jst.go.jp/article/jtm/25/4/25_4_108/_pdf
  41. https://bsapubs.onlinelibrary.wiley.com/doi/10.2307/3558330
  42. https://link.springer.com/article/10.1007/s13199-025-01057-y
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC11902086/
  44. https://ui.adsabs.harvard.edu/abs/2025Symbi..96...29C/abstract
  45. https://link.springer.com/article/10.1007/s13199-020-00685-w
  46. https://besjournals.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2745.2010.01716.x
  47. https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1421008/full
  48. https://www.mdpi.com/1420-3049/28/2/663
  49. https://digital.car.chula.ac.th/cgi/viewcontent.cgi?article=2842&context=tjps
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC4594322/
  51. https://www.researchgate.net/figure/Alkaloid-content-dry-weight-of-different-species-of-Ephedra-After-Ref-5_tbl1_231851270
  52. https://www.sciencedirect.com/science/article/abs/pii/S0031942210001214
  53. https://pubs.acs.org/doi/10.1021/ja00093a019
  54. https://www.sciencedirect.com/science/article/abs/pii/S0040403901886263
  55. https://pdfs.semanticscholar.org/8b97/ded1919f995e12f58444213bcac11155d650.pdf
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC11371322/
  57. https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/cbic.202500279
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC6120201/
  59. https://journals.sagepub.com/doi/10.4997/JRCPE.2011.116
  60. https://www.ncbi.nlm.nih.gov/books/NBK547661/
  61. https://go.drugbank.com/drugs/DB01364
  62. https://jpet.aspetjournals.org/article/S0022-3565%2825%2905630-7/fulltext
  63. https://go.drugbank.com/drugs/DB01363
  64. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/ephedra
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC9863261/
  66. https://pubmed.ncbi.nlm.nih.gov/12087345/
  67. https://www.sciencedirect.com/science/article/abs/pii/S0168851010002010
  68. https://www.gao.gov/assets/gao-03-1042t.pdf
  69. https://www.federalregister.gov/documents/2004/02/11/04-2912/final-rule-declaring-dietary-supplements-containing-ephedrine-alkaloids-adulterated-because-they
  70. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-final-rule-declaring-dietary-supplements-containing-ephedrine
  71. https://www.herbalgram.org/resources/herbalgram/issues/61/table-of-contents/article2658/
  72. https://www.healthline.com/nutrition/ephedra-sinica
  73. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/ephedra
  74. https://www.rand.org/pubs/research_briefs/RB4556.html
  75. https://www.mdpi.com/1424-8247/14/11/1198
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC11557485/
  77. https://www.sciencedirect.com/science/article/pii/S1879729614001665
  78. https://pubmed.ncbi.nlm.nih.gov/15991150/
  79. https://www.nejm.org/doi/full/10.1056/NEJM200012213432502
  80. https://www.cdc.gov/mmwr/preview/mmwrhtml/00043335.htm
  81. https://pubmed.ncbi.nlm.nih.gov/15625222/
  82. https://pubmed.ncbi.nlm.nih.gov/12639079/
  83. https://www.acpjournals.org/doi/10.7326/0003-4819-139-5_Part_1-200309020-00017
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC99410/
  85. https://trid.trb.org/View/476178
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC3621369/
  87. https://food.ec.europa.eu/document/download/caebf47c-0c63-4b01-bd9c-b736fe5b1bfc_en?filename=labelling_nutrition-vitamins_minerals-sa_ephedra_supp_en.pdf
  88. https://pubmed.ncbi.nlm.nih.gov/16086703/
  89. https://academic.oup.com/aje/article/168/8/966/137967
  90. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1397247/full
Add your contribution
Related Hubs
User Avatar
No comments yet.